---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-003154"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:47:17.988018+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corvus reports Q1 2026 net loss of $13.7M; cash $236.7M; soquelitinib trials advance

## Summary
- Net loss $13.7M in Q1 2026 vs net income $15.2M in Q1 2025; cash $236.7M (incl. $189.4M from Jan 2026 financing).
- Phase 2 atopic dermatitis trial initiated (~200 patients, 4 dose cohorts, 12-week treatment).
- Phase 3 registrational PTCL trial enrolling 150 patients; primary endpoint progression-free survival.
- Partner Angel Pharma enrolling Phase 1b/2 atopic dermatitis trial in China; initial results expected late 2026.
- New immunologic/biomarker data from Phase 1 to be presented at SID meeting on May 14, 2026.

## SEC filing metadata
- accession: 0001171843-26-003154
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184326003154/0001171843-26-003154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184326003154/f8k_050726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-003154
- JSON: https://secwatch.observer/filing/0001171843-26-003154.json
- Plain text: https://secwatch.observer/filing/0001171843-26-003154.txt

## Source-grounded claims
- claim_id: 3a9fe060225e24b7c709ecb6057e6ff16933bbb0
  claim: Corvus Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $13.7 million.
  evidence_excerpt: Net loss for the three months ended March 31, 2026 was $13.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626971/000117184326003154/0001171843-26-003154-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.